Acorn Asks For More Help From Investors After FDA Panel Denies CorCap PMA
This article was originally published in The Gray Sheet
Executive SummaryAcorn Cardiovascular says it will ask its current investors to fund a confirmatory trial of its CorCap Cardiac Support Device after an FDA advisory panel decided more research is needed before it could support premarket approval
You may also be interested in...
BioVentrix Inc. is developing a unique, minimally invasive approach to reshaping the heart’s scarred and enlarged left ventricle aimed at patients who develop ischemic heart failure following a heart attack. The company has made considerable headway with its technology, which offers an interesting balance between a catheter-based and surgical-based procedure; however, CEO Kenneth Miller, well aware of the pitfalls that have plagued earlier companies in this field, is taking a cautious approach to the US market.